Short answer
LENZ Therapeutics, Inc. (LENZ) filed its Q3 2025 10-Q quarterly report on Nov 5, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $13M with net income of −$17M.
Q3 2025 key financials · XBRL
- Revenue
- $13M
- +150.0% QoQ
- Net income
- −$17M
- −63.5% YoY · −12.0% QoQ
- Operating margin
- -151.1%
- EPS (diluted)
- −$0.59
- −268.7% YoY · −11.3% QoQ
Source: XBRL data from the LENZ Therapeutics, Inc. (LENZ) Q3 2025 10-Q on SEC EDGAR. USD.
LENZ Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $12.5M vs $0 YoY, entirely from license revenue
- Net loss $16.7M vs $10.2M YoY, with SG&A $27.6M, up 325%
- R&D $3.8M vs $6.5M YoY, down 41%; no segment or product-line revenue disclosed
- Cash, equivalents, restricted cash, and marketable securities $202.2M at September 30, 2025
- Nine-month ATM proceeds $26.1M; management expects cash sufficient to reach positive operating cash flow, but additional financing possible
Risk Factors
- Newly triggered commercialization risk: FDA approval of VIZZ in July 2025 and U.S. launch in August 2025 ended pre-commercial operations
- Market-acceptance risk: Qlosi launched April 2025 and generic Vuity launched August 2025, intensifying presbyopia competition
- Regulatory risk: VIZZ requires continued FDA compliance, including cGMP requirements and post-marketing commitments
- Operational risk: Commercialization depends entirely on VIZZ, with no additional product candidates in the current pipeline
- Financial risk: Net loss $16.7 million in Q3 2025 and accumulated deficit $191.2 million as of September 30, 2025
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other LENZ Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.